Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > GENEREX INKS $50 MILLION LICENSING DEAL WITH CHINA PARTNERS

<< Previous

Bullboard Posts

Next >>

Comment by Padinaon Nov 20, 2020 10:31am

62 Views

Post# 31940242

RE:RE:RE:RE:RE:RE:RE:RE:RE:GENEREX INKS $50 MILLION LICENSING DEAL WITH CHINA PARTNERS

It is possible for a platform to fail in A but the same platform, can suceed in B. Failure of a platform in a therapeutic area does not authomatically imply failure in others.
I look forward to a positive result but more importantly, i had wished the emphasis was on the oncology project. Too much drama & volatility associated with covid.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing